Literature DB >> 33504137

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin

Mustafa Şahin1, Mine Miskioğlu2, Işıl İnanır3, Hikmet Akar1, Nalan Neşe4, Peyker Temiz4, İsmet Aydoğdu2.   

Abstract

Entities:  

Keywords:  Cutaneous anaplastic large cell lymphoma; Brentuximab; Monotherapy; Breast cancer

Mesh：

Substances：

Year:  2020        PMID： 33504137      PMCID： PMC7927435          DOI： 10.4274/tjh.galenos.2020.2020.0512

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN： 1300-7777            Impact factor:   1.831


× No keyword cloud information.
  5 in total

1.  Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Willemze; E Hodak; P L Zinzani; L Specht; M Ladetto
Journal:  Ann Oncol       Date:  2013-07-17       Impact factor: 32.976

2.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Authors:  H Miles Prince; Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy M Kuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic
Journal:  Lancet       Date:  2017-06-07       Impact factor: 79.321

4.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Authors:  Steven Horwitz; Owen A O'Connor; Barbara Pro; Tim Illidge; Michelle Fanale; Ranjana Advani; Nancy L Bartlett; Jacob Haaber Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Tatyana Feldman; Anne Lennard; David Belada; Árpád Illés; Kensei Tobinai; Kunihiro Tsukasaki; Su-Peng Yeh; Andrei Shustov; Andreas Hüttmann; Kerry J Savage; Sam Yuen; Swaminathan Iyer; Pier Luigi Zinzani; Zhaowei Hua; Meredith Little; Shangbang Rao; Joseph Woolery; Thomas Manley; Lorenz Trümper
Journal:  Lancet       Date:  2018-12-04       Impact factor: 79.321

5.  Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.

Authors:  Takashi Onaka; Tomoya Kitagawa; Chika Kawakami; Akihito Yonezawa
Journal:  Turk J Haematol       Date:  2018-02-02       Impact factor: 1.831
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.